Ep. 3: Liver Toxicity, Risk Stratification, and Personalized Adjuvant Therapy in Early-Stage HR-Positive Disease
Key Points
-
Elevated liver enzymes require careful monitoring, comanagement, and consideration of drug interactions, with selective steroid use for severe toxicity.
-
High-risk T2N0 patients may benefit from CDK4/6 inhibitors, but therapy should be individualized based on genomic risk and overall prognosis.
-
Sentinel lymph node status, molecular features, and tumor biology help guide treatment eligibility and avoid under- or overtreatment.
-
Selection between ribociclib and abemaciclib should account for adverse effect profiles, comorbidities, and patient preference.
Navigating Toxicities, Risk Stratification, and Treatment Selection
Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, and Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, continued the discussion on adjuvant therapy for early-stage HR-positive breast cancer, focusing on managing toxicities, selecting patients, and balancing the risks of over- or undertreatment with CDK4/6 inhibitors. Sara Hurvitz, MD, FACP, of Fred Hutchinson Cancer Center; Sherry Shen, MD, of Memorial Sloan Kettering Cancer Center; and Eleonora Teplinsky, MD, of Valley-Mount Sinai Comprehensive Cancer Care, shared insights on liver enzyme elevations, drug interactions, and personalized therapy strategies.
The panel highlighted that elevated liver enzymes require careful evaluation, often in collaboration with a gastroenterologist or hepatologist. Steroids may be used for severe toxicity, practice patterns vary. Clinicians must also consider drug interactions, including concurrent use of statins and endocrine therapy, when evaluating liver enzyme elevations.
Assessing Risk and Potential Overtreatment
Dr. Shen addressed concerns about treating high-risk T2N0 patients. Applying NATALEE criteria, these patients, such as those with grade 3 disease or high genomic risk, may have prognoses similar to N1 disease and therefore derive meaningful benefit from adjuvant CDK4/6 inhibitors. However, not all T2N0 patients have the same risk, which underscores the importance of individualized counseling that weighs 3 years of treatment, adverse effects, and intensive monitoring against expected benefits.
The discussion also explored the evolving landscape of omitting sentinel lymph node biopsy. Nodal status is critical for guiding eligibility for ribociclib or abemaciclib, although molecular and biological markers, including Ki-67 and genomic risk scores, can help inform decisions. Tumor boards and shared decision-making remain essential to integrate tumor biology, patient preferences, and quality-of-life considerations.
Dr. Shen noted that clinical practice is evolving as long-term survival data become available. For patients eligible for both drugs, decisions often rely on adverse effect profiles and comorbidities—for example, presence of inflammatory bowel disease or fatty liver disease may favor one agent over the other. Both agents are effective, but patient-specific considerations guide optimal therapy selection.